Ekso Bionics (EKSO) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a sell rating to a hold rating in a research report released on Wednesday.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, ValuEngine lowered shares of Ekso Bionics from a buy rating to a hold rating in a report on Tuesday, October 2nd.

Shares of Ekso Bionics stock traded up $0.08 during mid-day trading on Wednesday, hitting $1.97. The stock had a trading volume of 2,829 shares, compared to its average volume of 249,876. Ekso Bionics has a 12-month low of $1.02 and a 12-month high of $4.77. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.17 and a quick ratio of 1.92. The stock has a market cap of $114.36 million, a price-to-earnings ratio of -2.22 and a beta of -0.34.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 327.12% and a negative return on equity of 169.75%. The firm had revenue of $2.97 million during the quarter, compared to analysts’ expectations of $3.03 million. Equities analysts expect that Ekso Bionics will post -0.45 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Ekso Bionics stock. Bristol Advisors LLC bought a new position in shares of Ekso Bionics Holdings Inc (NASDAQ:EKSO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 45,532 shares of the company’s stock, valued at approximately $107,000. Bristol Advisors LLC owned approximately 0.07% of Ekso Bionics as of its most recent SEC filing. 38.43% of the stock is owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Read More: How to invest in a bear market

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply